Imatinib in the Treatment of Colorectal Cancer—Molecular Targets, Preclinical Evidence and Clinical Limitations
Molecules · 01.11.2026 · 31 (21) · 3933
DOI: 10.3390/molecules31213933 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 01.11.2026. Verfasst von Katarzyna Wanke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland. Hauptthemen laut MEDLINE: Imatinib Mesylate, Colorectal Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a major therapeutic challenge, despite substantial advances in molecular characterization and targeted treatment. The heterogeneity of CRC and the development of treatment resistance highlight the need for novel therapeutic strategies and rational drug repurposing approaches. Imatinib, a well-established tyrosine kinase inhibitor, exerts pharmacological activity beyond ABL1/ABL2, targeting KIT, PDGFR, DDR1, and potentially LCK, which may contribute to distinct mechanisms of CRC progression. This review examines the emerging evidence on the potential role of imatinib in CRC, including its effects on tumor-cell proliferation and survival, invasion and metastasis, extracellular-matrix remodeling, tumor–stroma interactions, treatment resistance, and immune regulation. Preclinical studies indicate promising antitumor activity in selected molecular and biological contexts, particularly in KIT-positive tumors, PDGFR-rich stroma, mesenchymal/CMS4 tumors, and models characterized by aberrant DDR1 signaling. However, clinical evidence remains limited and does not currently support imatinib as a standard treatment for unselected CRC. Biomarker-guided patient selection, rational combination strategies, and tumor microenvironment-directed approaches may enhance its therapeutic potential. Further well-designed clinical studies are required to determine whether these biological effects can translate into meaningful clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland.
- Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-237 Lodz, Poland.
ORCID-Profile: Katarzyna Wanke, Mateusz Kciuk, Beata Marciniak, Renata Kontek
Zitieren
APA
Wanke, K., Kciuk, M., Marciniak, B., & Kontek, R. (2026). Imatinib in the Treatment of Colorectal Cancer—Molecular Targets, Preclinical Evidence and Clinical Limitations. Molecules, 31(21), 3933. https://doi.org/10.3390/molecules31213933
Vancouver
Wanke K, Kciuk M, Marciniak B, Kontek R. Imatinib in the Treatment of Colorectal Cancer—Molecular Targets, Preclinical Evidence and Clinical Limitations. Molecules. 2026;31(21):3933. doi:10.3390/molecules31213933
BibTeX
@article{Wanke2026,
author = {Wanke, Katarzyna and Kciuk, Mateusz and Marciniak, Beata and Kontek, Renata},
title = {Imatinib in the Treatment of Colorectal Cancer—Molecular Targets, Preclinical Evidence and Clinical Limitations},
journal = {Molecules},
year = {2026},
volume = {31},
number = {21},
pages = {3933},
doi = {10.3390/molecules31213933}
}
EUVIMED